NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » Company watch » Contract Research Orgs  1  2  3  4  5  » 
found files: 135
Charles River »23/03/2007 [Company watch]
Charles River commits to large expansion programme in Shanghai

Charles River Laboratories International, Inc. (NYSE:CRL) announced today the expansion of its global footprint in Asia as part of its strategy to support customers' research and development efforts in this rapidly growing market....   more»

Shanghai ChemPartner Co.,Ltd. »25/04/2007 [Company watch]
Biotage, Chempartner sign multi-instrument deal

Shanghai Chempartner Co., Ltd., one of China’s leading contract research organizations (CRO), has invested in Biotage SP automated flash instruments and Initiator microwave synthesizers with delivery scheduled over the next 12 months. This is Biotage's largest single order in China at a value of $1.48 m....   more»

Covance »30/04/2007 [Company watch]
First Quarter 07 Results

copy of results...   more»

Charles River »08/05/2007 [Company watch]
Charles River announces 1st Quarter 2007 results

see full report...   more»

Charles River »24/04/2007 [Company watch]
Charles River Laboratories Appoints Cheri Walker, Ph.D. as Corporate Senior Vice President, Corporate Development

Charles River Laboratories International, Inc. (NYSE: CRL) announced today the appointment of Cheri Walker, Ph.D. to the role of Corporate Senior Vice President, Corporate Development, effective April 24, 2007. Dr. Walker will be responsible for the Company's global corporate development function, directing all aspects of our merger, acquisition and strategic joint venture activities. She will also participate as an integral member in the strategic planning process of the Company. Prior to joining Charles River, Dr. Walker was Vice President, Mergers and Acquisitions for QIAGEN Sciences where she oversaw the corporate development of QIAGEN's North American life sciences tools and molecular diagnostics businesses. Previously, Dr. Walker held senior corporate development and operational positions at Invitrogen where she successfully executed acquisition and licensing transactions. James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories noted, "We are delighted to have Cheri join the Charles River team. Her depth of experience in life science transactions adds greater strength to our management team." Dr. Walker commented, "I have followed the growth of Charles River for several years and am very excited to be joining a dynamic and expanding company. Corporate Development will play an integral role in this growth and I am looking forward to being part of the team." Dr. Walker holds a doctorate in Human and Molecular Genetics from Baylor College of Medicine and a bachelor's degree in Biology from Swarthmore College....   more»

Sundia MediTech Company,Ltd. »06/06/2007 [Company watch]
China CROs Merge

Sundia MediTech and Shanghai United PharmaTech report that they will be merging. This is a first for China’s young CRO industry, acording to Sundia’s CEO, Wang Xiaochuan, Ph.D. Both Xiaochuan and United PharmaTech’s CEO, Shi Xiongwei, Ph.D., signed a letter of intent agreeing to combine their two companies. Under the terms of the merger, both United PharmaTech and Sundia MediTech will become subsidiaries of Sundia Investment Group, the British Virgin Islands-based holding company that currently owns Sundia MediTech. Dr. Wang will become the new company’s chairman and CEO, while Dr. Shi will hold the positions of director and executive vp. The former senior management teams of both companies will join together into a new, combined management team. Zhang Suyang, a partner of IDG VC, said that he believes China’s drug development CRO industry is beginning to emerge from its initial state into one in which companies will begin to consolidate. “The CRO companies, and the overall size of the CRO industry in China are still relatively small, and there is huge potential for growth, so we can expect that in the following few years there will be many mergers,” explained Zhang. “Companies in this industry will grow quickly and soon; we will see companies of reasonable size and with good governance emerge as corporations with serious long-term potential.” Part of the reason for the merger, noted Dr. Wang, is that it will combine United PharmaTech’s and Sundia’s technical expertise in different fields....   more»

Charles River »10/06/2007 [Company watch]
Charles River Laboratories (CRL) will begin operating in China, establishing a joint venture with Shanghai BioExplorer Co., Ltd,

Charles River Laboratories (CRL) will begin operating in China, establishing a joint venture with Shanghai BioExplorer Co., Ltd, a Shanghai company that, like Charles River, provides pre-clinical CRO (Contract Research Organization) services. As one of the top two U.S. CROs, the menu of Charles River offerings are somewhat larger than BioExplorer's, although these will be expanded to meet the stated goal of supporting its customers’ needs, from drug discovery through proof of concept on a global basis....   more»

Sundia MediTech Company,Ltd. »08/06/2007 [Company watch]
Sundia Meditech Company, Ltd. celebrated its recent strong growth at the company's third anniversary party in Shanghai.

The main business of this company is to provide contracted research (CRO) services to pharmaceutical and biotech company clients worldwide. Earlier this week, the company announced a merger in process with United Pharmatech Company, another CRO company in Shanghai....   more»

Wuxi Pharma Tech
»06/07/2007 [Company watch]
IPO for WuXi PharmaTech?

Outsourcing powerhouse WuXi PharmaTech is rumored to be on the verge of announcing its IPO. The Shanghai-based company has been a huge success story right from the outset of its 2001 startup, now boasting 1,550 scientific staff members and over 2,000 employees overall....   more»

Wuxi Pharma Tech »25/07/2007 [Company watch]
Wuxi Pharma TechPlans $120Million US public offering

WuXi PharmaTech, the biggest Chinese contract research organisation (CRO), has put an end to weeks of speculation by officially announcing it plans an initial public offering (IPO) on the New York Stock Exchange....   more»

Sundia MediTech Company,Ltd.
»12/07/2007 [Company watch]
CRO Company Sundia Named One of China\\\'s Top 50 to Invest In

Today, Sundia MediTech (Shanghai) Company was named one of the 50 best companies for investment in China by the top venture capital investors. Sundia ranked #16 of Venture 50, an event organized by Zero2IPO, an advisory firm for China investment....   more»

Bridge (Vital Bridge) »08/08/2007 [Company watch]
Bridge Pharma\\\\\\\'s China facility receives AAALAC accreditation

US-based Bridge Pharmaceuticals’ facility in China has been awarded full accreditation by the Council on Accreditation of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC International).Bridges facility in Beijing (Vital Bridge China) is one of only seven toxicology facilities in China to receive this recognition, and Bridge claims that it is the first US-based company to offer toxicology services in multispecies at both locations in the US and China....   more»

Wuxi Pharma Tech »10/08/2007 [Company watch]
Wuxi Raises $185Million from IPO

The NYSE listing of the Chinese drug research company receives substantial demand, enabling it to price 8% higher than the top of the range....   more»

VENTURE PHARM SERVICE--VPScro »27/07/2007 [Company watch]
Raising HK$ 97 million-- VPS-CRO---- A Chinese Leader in Preclinical & Clinical Service Is Ready To Run

On 27 July 2007, the Company and a Swiss financial corporation, entered into the Note Purchase Agreement in respect of the issue of the Convertible Notes in the principal amount of CHF 15 million (approximately HK$ 97.2 million) due 2012....   more»

Wuxi Pharma Tech »19/08/2007 [Company watch]
China\'s WuXi PharmaTech adds 3 senior level positions to management

China\'s WuXi PharmaTech, a New York Stock Exchange-listed provider of pharmaceutical research and development outsourcing services, said it has added three senior level positions to its management, namely executive vice president of operations, vice president of toxicology and vice president of finance....   more»

Hutchison China MediTech Limited(“Chi-Med”) »20/08/2007 [Company watch]
Hutchison China Medipharma agrees collaboration deal with Eli Lilly

Hutchison China Meditech, the China-based pharmaceutical company, said its unit Hutchison MediPharma has agreed a research collaboration with US pharmaceutical company Eli Lilly (NYSE:LLY) to co-develop oncology and anti-inflammatory medicines. Hutchison said it will receive milestone payments of 20-29 mln usd, depending on the clinical candidate, along with an upfront fee, annual research and development support costs and also potential royalties. Under the terms of the agreement, Hutchison will take responsibility for initial research and development, while Eli Lilly will offer technological advice and clinical trial expertise as the project advances. The research will be carried out in China to 'expedite the drug discovery process and reduce overall costs', Hutchison said....   more»

Covance »30/08/2007 [Company watch]
Covance Advances on its Shanghai Lab

Interestingly, Covance said its increased presence in China was due to the higher level of pharmaceutical activity there. Usually, companies invest in China because of some combination of low costs or interest in the country’s growing market for drugs. Because China is expected to be the fifth largest market in the world by 2010 – just three years away – Covance felt the need to be a part of this vital area of pharmaceutical enterprise, to be close to the action. Covance is a $4.5 billion contract research organization with revenues of $1.5 billion annually. During the last week, we noted that big pharma was choosing to build new facilities in China rather than India (see story). Then Novartis (NVS), which just last year announced its intention to make major investments in both countries, reneged on its commitment to India (see story). The cause underlying both stories was poor patent protection in India. For Novartis, the decision was made after the company lost a patent infringement suit against a generic version of leukemia drug Gleevec. Also in the news last week, Beijing Med-Pharm (BJGP) raised $31 million that will allow the company to continue its acquisitive ways (see story), China Shenghuo (KUN) reported much improved Q2 results (see story), Optimer Pharma (OPTR) entered talks with C&O Pharma (of Taiwan, Hong Kong and China) to discuss future collaborations (see story), and China decided to allow its citizens the right to invest in Hong Kong-listed stocks (see story). The change may have the effect of making Hong Kong a more-preferred exchange for biomedical enterprises that are planning their IPOs....   more»

Wuxi Pharma Tech »04/09/2007 [Company watch]
WuXi PharmaTech Co., Ltd. Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007

SHANGHAI, China, Sept. 4 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. ("WuXi PharmaTech" or ''the Company''), the leading China- based pharmaceutical and biotechnology research and development outsourcing company, today announced that it will release unaudited financial results for the second quarter ended June 30, 2007 before the US market opens on Thursday, September 6, 2007.(...   more»

Wuxi Pharma Tech »24/08/2007 [Company watch]
WuXi PharmaTech Co., Ltd. CEO Appointed to CrossFire Beilstein Database Advisory Board

SHANGHAI, China, Aug. 24 /Xinhua-PRNewswire/ -- WuXi PharmaTech , China's premier provider of pharmaceutical R&D outsourcing services announced today Dr. Ge Li, the Company's Chairman and Chief Executive Officer, is appointed to a newly established advisory board of Elsevier Information Systems GmbH....   more»

Covance »17/09/2007 [Company watch]
Covance nominates Bi Honggang as VP, GM in China

Covance, the world's second largest contract research organization (CRO), recently announced the successful nomination of Bi Honggang as Vice President and General Manager, China. Bi will lead Covance's business activities in China and represent Covance in its regulatory activities with the Chinese government. Bi Honggang received his Ph.D. in chemistry and drug metabolism from McGill University in Montreal, Canada, and has more than 15 years experience in pharmaceutical research and development at companies including SmithKline Beecham, Parke-Davis, and Pfizer. Before joining Covance, Bi worked as Chief Executive Officer of Frontage Laboratories in Malvern, Pa. Covance established its first clinical office in Beijing in 1998 and recently opened its fifth global central laboratory in Shanghai, China....   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.